Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,128 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effects of itraconazole and rifampicin on the single-dose pharmacokinetics of the nonsteroidal mineralocorticoid receptor blocker esaxerenone in healthy Japanese subjects.
Kirigaya Y, Shiramoto M, Ishizuka T, Uchimaru H, Irie S, Kato M, Shimizu T, Nakatsu T, Nishikawa Y, Ishizuka H. Kirigaya Y, et al. Among authors: ishizuka h, ishizuka t. Br J Clin Pharmacol. 2020 Oct;86(10):2070-2079. doi: 10.1111/bcp.14302. Epub 2020 May 13. Br J Clin Pharmacol. 2020. PMID: 32250463 Free PMC article.
Effects of Repeated Oral Administration of Esaxerenone on the Pharmacokinetics of Midazolam in Healthy Japanese Males.
Toyama K, Furuie H, Kuroda K, Ishizuka T, Okuda Y, Shimizu T, Kato M, Igawa Y, Nishikawa Y, Ishizuka H. Toyama K, et al. Among authors: ishizuka h, ishizuka t. Eur J Drug Metab Pharmacokinet. 2021 Sep;46(5):685-694. doi: 10.1007/s13318-021-00701-4. Epub 2021 Aug 12. Eur J Drug Metab Pharmacokinet. 2021. PMID: 34383278 Free PMC article. Clinical Trial.
Physiologically based pharmacokinetic modelling to predict the clinical effect of CYP3A inhibitors/inducers on esaxerenone pharmacokinetics in healthy subjects and subjects with hepatic impairment.
Watanabe A, Ishizuka T, Yamada M, Igawa Y, Shimizu T, Ishizuka H. Watanabe A, et al. Among authors: ishizuka h, ishizuka t. Eur J Clin Pharmacol. 2022 Jan;78(1):65-73. doi: 10.1007/s00228-021-03194-x. Epub 2021 Aug 20. Eur J Clin Pharmacol. 2022. PMID: 34415382 Free PMC article. Clinical Trial.
Absolute Bioavailability of Esaxerenone and Food Effects on its Pharmacokinetics After a Single Oral Dose in Healthy Japanese Subjects: An Open-Label Crossover Study.
Kurata A, Furuie H, Ishizuka T, Nakatsu T, Shimizu T, Kato M, Nishikawa Y, Ishizuka H. Kurata A, et al. Among authors: ishizuka h, ishizuka t. Adv Ther. 2019 Jul;36(7):1618-1627. doi: 10.1007/s12325-019-00956-z. Epub 2019 May 22. Adv Ther. 2019. PMID: 31119692 Free PMC article. Clinical Trial.
Correction to: Physiologically based pharmacokinetic modelling to predict the clinical effect of CYP3A inhibitors/inducers on esaxerenone pharmacokinetics in healthy subjects and subjects with hepatic impairment.
Watanabe A, Ishizuka T, Yamada M, Igawa Y, Shimizu T, Ishizuka H. Watanabe A, et al. Among authors: ishizuka h, ishizuka t. Eur J Clin Pharmacol. 2022 Jan;78(1):75. doi: 10.1007/s00228-021-03211-z. Eur J Clin Pharmacol. 2022. PMID: 34494163 Free PMC article. No abstract available.
1,128 results